Independent directory Public ClinicalTrials.gov records United States
ClinicalTrials.gov record
Terminated Phase 2 Interventional Results available

Safety and Efficacy of Efavaleukin Alfa in Participants With Moderately to Severely Active Ulcerative Colitis

ClinicalTrials.gov ID: NCT04987307

Public ClinicalTrials.gov record NCT04987307. Field values are reproduced from the official study page; the official ClinicalTrials.gov record remains the source of truth for eligibility, enrollment, and contact information.

ClinicalTrials.gov public records Last synced Sep 2, 2026, 11:20 AM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Official title

A Phase 2, Dose-finding, Randomized, Double-blind, Placebo-controlled, Multicenter Study to Evaluate the Safety and Efficacy of Efavaleukin Alfa Induction Therapy in Subjects With Moderately to Severely Active Ulcerative Colitis

Brief summary

Reproduced verbatim from the official ClinicalTrials.gov record. Not medical advice.

The main purpose of this study is to evaluate the effect of efavaleukin alfa on induction of clinical remission in participants with moderately to severely active ulcerative colitis (UC). Participants will be randomized to receive 1 of 3 efavaleukin alfa doses or placebo during a 12-week induction period. Participants who complete the 12-week induction period will have the option to enter an exploratory long-term treatment period for up to 40 weeks (total of up to 52 weeks of treatment) if, in the opinion of the investigator, they may benefit from continued treatment. During the long-term period, participants randomized to efavaleukin alfa will remain on the same efavaleukin alfa blinded dose; participants randomized to placebo who achieved clinical response at week 12 will remain on placebo; and placebo non-responders (ie, participants randomized to placebo who did not achieve clinical response at week 12) will receive efavaleukin alfa in a blinded manner during continued treatment. All participants will complete a safety follow-up visit 6 weeks after their last dose of investigational product.

Study identification

NCT ID
NCT04987307
Recruitment status
Terminated
Study type
Interventional
Phase
Phase 2
Lead sponsor
Amgen
Industry
Enrollment
221 participants

Conditions and interventions

Interventions

Drug

Eligibility (public fields only)

Age range
18 Years to 80 Years
Sex
All
Healthy volunteers
Healthy volunteers not accepted

This page does not interpret eligibility. Detailed inclusion and exclusion criteria are on the official ClinicalTrials.gov record.

Study timeline

Start date
Jan 30, 2022
Primary completion
Oct 21, 2024
Completion
Oct 21, 2024
Last update posted
Jan 12, 2026

2022 – 2024

United States locations

U.S. sites
63
U.S. states
27
U.S. cities
60
Facility City State ZIP Site status
Digestive Health Specialists of the Southeast Dothan Alabama 36305
Birmingham Digestive Health Research, LLC Homewood Alabama 35209
Arizona Health Research Mesa Arizona 85206
Arizona Arthritis and Rheumatology Research, PLLC Phoenix Arizona 85037
Southern California Research Center Coronado California 92118
United Medical Doctors Los Alamitos California 90720
Biopharma Informatic Incorporated Los Angeles California 90035
Gastrointestinal Biosciences Clinical Trials Limited Liability Company Los Angeles California 90067
University of California Irvine Orange California 92868
Santa Maria Gastroenterology Medical Group Santa Maria California 93458
Clinical Trials Management Services LLC Thousand Oaks California 91360
Gastroenterology Center of Connecticut, PC Hamden Connecticut 06518
West Central Gastroenterology Clearwater Florida 33756
Homestead Associates In Research Inc Homestead Florida 33032
Indian Health Service Health Research Kissimmee Florida 34741
Lake Center for Clinical Research Lady Lake Florida 32159
Auzmer Research Lakeland Florida 33813
University of Miami Hospital and Clinic Miami Florida 33136
Ocala Gastrointestinal Research, LLC Ocala Florida 34471
AdventHealth Medical Group Gastroenterology and Hepatology Orlando Florida 32804
Infigo Clinical Research Sanford Florida 32771
Atlanta Gastroenterology Associates Atlanta Georgia 30342
Columbus Regional Research Institute, LLC Columbus Georgia 31901
Grand Teton Research Group Idaho Falls Idaho 83404
Rush University Medical Center Chicago Illinois 60612
Digestive Research Alliance of Michiana South Bend Indiana 46635
University of Kansas Medical Center Kansas City Kansas 66160
Mid-Atlantic GI Research, LLC Greenbelt Maryland 20770
Harvard Medical School - Brigham and Womens Hospital Boston Massachusetts 02115
University of Massachusetts Memorial Medical Center Worcester Massachusetts 01655
University of Michigan Ann Arbor Michigan 48109
Clinical Research Institute of Michigan Troy Michigan 48098
West Michigan Clinical Research Center Wyoming Michigan 49519
Southern Therapy and Advanced Research LLC - Jackson Jackson Mississippi 39216
Gastrointestinal Associates Research, LLC Columbia Missouri 65201
Bvl Clinical Research Liberty Missouri 64068
Interspond - Las Vegas Medical Research Las Vegas Nevada 89113
Sanmora Bespoke Clinical Research Solutions East Orange New Jersey 07018
Aga Clinical Research Associates LLC Egg Harbor New Jersey 08234
Affiliates in Gastroenterology Digestive Disease Research Florham Park New Jersey 07932
Atlantic Digestive Health Institute Morristown New Jersey 07960
Premier Health Research LLC Sparta New Jersey 07871
University of New Mexico Albuquerque New Mexico 87106
New York University Grossman School of Medicine and New York University Langone Hospitals Lake Success New York 11042
Consultants for Clinical Research Cincinnati Ohio 45219
Digestive Specialists Inc Research, LLC Springboro Ohio 45066
Hightower Clinical Oklahoma City Oklahoma 73102
Options Health Research, LLC Tulsa Oklahoma 74104
Guthrie Robert Packer Hospital Sayre Pennsylvania 18840
Medical University of South Carolina Charleston South Carolina 29425
Columbia Digestive Health Research LLC Columbia South Carolina 29204
Wake Research-ClinSearch, LLC Chattanooga Tennessee 37421
Digestive Health Research, LLC Hermitage Tennessee 37076
Great Lakes Research Insititute El Paso Research El Paso Texas 79912
Digestive Health Associates Houston Texas 77024
Digestive Research of Central Texas, LLC Waco Texas 76712
Digestive Health Research of North Texas LLC Wichita Falls Texas 76301
Emeritas Research Group Lansdowne Town Center Virginia 20176
Blue Ridge Medical Research Lynchburg Virginia 24502
North Richmond Health Research Richmond Virginia 23229
GI Select Health Research LLC Richmond Virginia 23236
Hunter Holmes McGuire Veterans Affairs Medical Center Richmond Virginia 23249
Wisconsin Center for Advanced Research Milwaukee Wisconsin 53215

Site contact phone numbers, emails, and investigator names are intentionally not displayed here. Open the official ClinicalTrials.gov record for site contact information.

Non-U.S. locations

This page focuses on the U.S. directory. The official record also lists 137 non-U.S. sites.

About this trial record page

What this page shows
Public field values for ClinicalTrials.gov record NCT04987307, including study identification, conditions, interventions, eligibility (age, sex, healthy volunteer), timeline, and U.S. site list.
What this page does not do
No medical advice, eligibility judgments, treatment recommendations, study quality scoring, or AI-generated medical summaries. No site contact phone numbers, emails, or investigator names.
Where the data comes from
Sourced from the official ClinicalTrials.gov public API. The official record is the source of truth.
Last refresh
Last update posted Jan 12, 2026 · Synced Sep 2, 2026

Related: full search, browse by condition, browse by drug or therapy, browse by sponsor, browse by U.S. city.

Open the official record

The complete protocol, eligibility criteria, and contact information for NCT04987307 live on ClinicalTrials.gov.

View official ClinicalTrials.gov record →